MedPage Today May 31, 2024
— Moderna vaccine indicated for people ages 60 and up
The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA) for respiratory syncytial virus (RSV) for people ages 60 and older to protect against lower respiratory tract disease, Moderna announced Friday in a press release.
“The FDA approval … builds on the strength and versatility of our mRNA platform,” Stéphane Bancel, chief executive officer of Moderna, said in the press release, noting that this is the first time an mRNA vaccine has been approved for a disease other than COVID-19.
The vaccine will be Moderna’s second marketed product, in addition to its SARS-CoV-2 mRNA-1273 vaccine (Spikevax).
The FDA’s approval of the mRNA-1345 vaccine is based on results from the phase III ConquerRSV...
Today's Sponsors
Today's Sponsor